TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29650037
Drug: Standard schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard schedule 4/2 (37.5 mg daily)
Study: 23263000
Drug: GS-9851 400
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-9851 400 mg once daily for 3 days
Study: 12829988
Drug: Ribavirin (1,000-1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (1,000-1,200 mg daily)
Study: 10996722
Drug: Chemotherapy (n=20;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (n=20; 1052 lymph nodes)
Study: 1797498
Drug: Human ultralente
Normalized name: INSULIN HUMAN ULTRALENTE 100 UNIT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human ultralente insulin before supper
Study: 6117537
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg lorazepam
Study: 21890585
Drug: TPA023 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPA023 (2 mg)
Study: 21890585
Drug: Alcohol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.6 g/L)
Study: 17475735
Drug: Weekly interpersonal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly interpersonal psychotherapy (IPT)
Study: 17475735
Drug: Twice-monthly interpersonal
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-monthly interpersonal psychotherapy (IPT)
Study: 17475735
Drug: Monthly interpersonal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly interpersonal psychotherapy (IPT)
Study: 17475735
Drug: IPT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPT with selective serotonin reuptake inhibitor (SSRI)
Study: 15025617
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of bupivacaine and 50 microg of morphine
Study: 15025617
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of bupivacaine and 25 microg of fentanyl
Study: 15025617
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of bupivacaine and saline
Study: 11283120
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m²/day for 5 days every 21 days)
Study: 11283120
Drug: Paclitaxel (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (175 mg/m² over 3 hours every 21 days)
Study: 7685226
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium (40-120 mg/day)
Study: 1474534
Drug: Naproxen (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (1000 mg/day)
Study: 29772695
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT‐A) injections
Study: 2254512
Drug: Behavioral Marital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Marital Therapy (BMT) Alone
Study: 6118980
Drug: Talinolol (cordanum)
Normalized name: talinolol
DrugBank: Talinolol (DB11770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talinolol (cordanum) administered intravenously and then orally
Study: 26253746
Drug: e-virtual reality
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-virtual reality exposure therapy (remote sessions)
Study: 26253746
Drug: traditional virtual
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: traditional virtual reality exposure therapy (in-person sessions)
Study: 22652990
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injections with 0.5% lidocaine mixed with 1 mL of steroid (nonparticulate Celestone)
Study: 7598235
Drug: Carbonated lidocaine
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbonated lidocaine (20 mL of 1.73% carbonated lidocaine with epinephrine 5 micrograms/mL plus 2 mL of 0.9% NaCl, pH 6.42 +/- 0.04)
Study: 7598235
Drug: pH adjusted
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH adjusted lidocaine (20 mL of lidocaine with epinephrine 5 micrograms/mL plus 2 mL of 8.4% sodium bicarbonate, pH 6.47 +/- 0.16)
Study: 7598235
Drug: Lidocaine HCl
Normalized name: lidocaine HCl
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine HCl (control group, 20 mL of 2% lidocaine with epinephrine 5 micrograms/mL plus 2 mL of NaCl 0.9%, pH 4.58 +/- 0.10)
Study: 2369808
Drug: Dihydroergotamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (0.5 mg)
Study: 146524
Drug: Intravenous physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous physostigmine
Study: 146524
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with oral choline chloride
Study: 146524
Drug: Single 5-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 5-g dose of choline chloride
Study: 414267
Drug: Chlorpromazine 75
Normalized name: chlorproMAZINE 75 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine 75 mg
Study: 29737796
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme 8371 USP unit of lipase, 3 times daily for 1 month
Study: 24131304
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg lebrikizumab administered subcutaneously every 4 weeks over 12 weeks (total of four doses)
Study: 24131304
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously every 4 weeks over 12 weeks (total of four doses)
Study: 24131304
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg lebrikizumab
Study: 15604157
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics at home
Study: 15604157
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics in hospital
Study: 10191283
Drug: Stanol ester
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanol ester margarine (2 or 3 g/day)
Study: 8703669
Drug: theophylline +
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: theophylline + 200 mg nefazodone twice daily (every 12h)
Study: 8703669
Drug: theophylline +
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: theophylline + matching nefazodone placebo capsule twice daily (every 12h)
Study: 8703669
Drug: theophylline +
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: theophylline + 200 mg nefazodone
Study: 25532515
Drug: rFSH +
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rFSH + GnRH antagonist (n = 45)
Study: 23619901
Drug: ICG-augmented diode
Normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICG-augmented diode laser therapy (ICG + DL) at a total dose of 4 mg/kg body weight
Study: 23619901
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) therapy before and after ICG administration (ICG + IPL)
Study: 19763572
Drug: High-dose HAIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HAIC (5-FU, 500 mg/m² on days 1-3 and cisplatin, 60 mg/m² on day 2)
Study: 19763572
Drug: Low-dose HAIC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HAIC (5-FU, 170 mg/m² and cisplatin, 7 mg/m² on days 1-5)
Study: 19763572
Drug: High-dose HAIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HAIC
Study: 19763572
Drug: Low-dose HAIC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose HAIC
Study: 18447211
Drug: Needle-pricking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle-pricking therapy combined with spinal massage
Study: 18447211
Drug: Azulfidine (medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azulfidine (medication group)
Study: 11192138
Drug: Amlodipine (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (once daily, morning or evening)
Study: 9159299
Drug: Sodium ramping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ramping (linear from 155 mEq/L to 140 mEq/L)
Study: 9159299
Drug: Standard dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dialysis (steady dialysate sodium of 140 mEq/L)
Study: 8439075
Drug: Nebulized L‐Adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized L‐Adrenaline and placebo (IM)
Study: 8439075
Drug: Nebulized L‐Adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized L‐Adrenaline and dexamethasone (IM)
Study: 3530030
Drug: Birch pollen
Normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch pollen preparation (n = 14) with doses up to 1.4 X 10(6) biologic units per day
Study: 3530030
Drug: Birch pollen
Normalized name: Gray birch pollen
DrugBank: Betula populifolia pollen (DB10724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birch pollen preparation (n = 14)
Study: 27255560
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% plus 8 mg dexamethasone
Study: 18761784
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg continuously once daily
Study: 18761784
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg on-demand
Study: 11130294
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (hGH) at a dose of 0.125 U.kg‐1.wk‐1 for four weeks and 0.25 U.kg‐1.wk‐1 thereafter
Study: 6384817
Drug: 5 X
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 X 10(6) IU of natural alpha interferon daily for 6 months
Study: 22205314
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (various doses from 0 to 2000 μg/d)
Study: 22205314
Drug: High-iodine intervention
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-iodine intervention groups (1500-2000 μg)
Study: 22205314
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg I supplementation
Study: 22205314
Drug: 500-2000 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-2000 μg I supplementation
Study: 20150398
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg per day + interferon beta-1a
Study: 17295573
Drug: Fluoxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine + Cognitive-Behavioral Therapy (CBT)
Study: 17295573
Drug: Fluoxetine only
Normalized name: Fluoxetine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine only (Medication-only group)
Study: 12353189
Drug: Valacyclovir 1000
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1000 mg twice daily for 1 day
Study: 12353189
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg twice daily for 3 days
Study: 1574336
Drug: Theophylline (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (150 mg/day)
Study: 3893703
Drug: clebopride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: clebopride (0.5 mg TID)
Study: 24899339
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all control measures
Study: 19641919
Drug: Intravenous temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous temozolomide (150 mg/m2 as a 90-min infusion)
Study: 19641919
Drug: Oral temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral temozolomide (200 mg/m2 on days 1, 2, and 5; 150 mg/m2 on days 3 and 4)
Study: 18593390
Drug: Standard moist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard moist wound-care therapy
Study: 12568976
Drug: 600 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/die valerian extract LI 156 (Sedonium)
Study: 12568976
Drug: 10 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/die oxazepam
Study: 9780763
Drug: 3‐in‐1 block
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐in‐1 block with 40 mL of 1.5% mepivacaine (T group, n = 20)
Study: 9780763
Drug: Subarachnoid puncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subarachnoid puncture with 3 mL of 2% lidocaine (S group, n = 20)
Study: 7932518
Drug: Lisinopril (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (20-40 mg daily)
Study: 7932518
Drug: Diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem SR (120-180 mg twice daily)
Study: 3219879
Drug: Combination inhaler
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination inhaler of salbutamol (800 micrograms) and beclomethasone dipropionate (400 micrograms)
Study: 29330194
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl 250 mg tid
Study: 29330194
Drug: Telotristat ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telotristat ethyl 500 mg tid
Study: 26756383
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of a dexamethasone implant (IVI‐DEX) after switching from bevacizumab (AD group)
Study: 26756383
Drug: Bevacizumab followed
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab followed by intravitreal injection of a dexamethasone implant (DA group)
Study: 25316130
Drug: Pirfenidone therapy
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone therapy (600 mg/day for 8 weeks) with add-on rikkunshi-to from week 4
Study: 25316130
Drug: Pirfenidone therapy
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone therapy (1200 mg/day)
Study: 23508526
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal system (≤ 16 mg/24 h)
Study: 18259028
Drug: 17beta‐estradiol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta‐estradiol (1 mg/d)
Study: 18259028
Drug: Enalaprilat (0.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (0.33 microg/min/100 mL forearm volume)
Study: 10958090
Drug: Unilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral spinal anesthesia with 8 mg hyperbaric bupivacaine 0.5%
Study: 10958090
Drug: Bilateral spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral spinal anesthesia with 8 mg hyperbaric bupivacaine 0.5%
Study: 8449845
Drug: Perioperative antibiotic
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative antibiotic prophylaxis (cephalosporins used in 86% of cases)
Study: 29237204
Drug: Aggressive intravenous
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive intravenous hydration with lactated Ringer's solution (3 mL/kg/h during ERCP, a 20-mL/kg bolus, and 3 mL/kg/h for 8 hours after ERCP)
Study: 29237204
Drug: Aggressive intravenous
Normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive intravenous hydration with normal saline solution (3 mL/kg/h during ERCP, a 20-mL/kg bolus, and 3 mL/kg/h for 8 hours after ERCP)
Study: 29237204
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous hydration with lactated Ringer's solution (1.5 mL/kg/h during and for 8 hours after ERCP)
Study: 22281609
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg emodin
Study: 22281609
Drug: 700 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 mg/kg vitamin C (Vc)
Study: 22281609
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg emodin + 700 mg/kg vitamin C (Vc)
Study: 22281609
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (basal diet with 50.3 mg/kg Vc)
Study: 18514746
Drug: Scopolamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopolamine (0.3 mg subcutaneous)
Study: 18514746
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 mg oral)
Study: 12734150
Drug: CSL 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL 1.5 mL.kg(‐1) per hour fasting duration
Study: 12734150
Drug: CSL 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL 1.5 mL.kg(‐1) per hour fasting duration with 0.5 g.kg(‐1) dextrose added
Study: 26773557
Drug: IDegAspSimple titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegAspSimple titration algorithm
Study: 26773557
Drug: IDegAspStepwise titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDegAspStepwise titration algorithm
Study: 26093487
Drug: Effect-site remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect-site remifentanil concentration before bolus administration
Study: 23216875
Drug: Low effect-site
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low effect-site concentration of propofol (1.5-2.5 μg/mL)
Study: 23216875
Drug: High effect-site
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High effect-site concentration of propofol (3.0-4.0 μg/mL)
Study: 16601984
Drug: Anti-inflammatory drug
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory drug for 2 weeks
Study: 16601984
Drug: No anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-inflammatory drug (control)
Study: 14562669
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker therapy
Study: 14562669
Drug: No beta
Normalized name: Amidino beta-alanine
DrugBank: Ompenaclid (DB18819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta blocker therapy (Control)
Study: 1476277
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of 1 mg.kg‐1 of morphine (group 2)
Study: 1476277
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of 2 mg.kg‐1 of morphine (group 3)
Study: 1476277
Drug: i.v. boluses
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. boluses of 2 mg of morphine (group 1)
Study: 6144620
Drug: Nitrefazole 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrefazole 800 mg (4 capsules of 200 mg)
Study: 6144620
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules of identical appearance)
Study: 28482641
Drug: Bryostatin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin (25 μg/m2)
Study: 18279623
Drug: Ropivacaine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine and morphine through thoracic epidural preoperatively (group PE)
Study: 18279623
Drug: Ropivacaine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine and morphine through thoracic epidural postoperatively (group E)
Study: 18279623
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of fentanyl postoperatively (group IV)
Study: 8955966
Drug: Intramuscular clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular clonidine (300 micrograms)
Study: 1573044
Drug: buspirone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (20 mg)
Study: 1573044
Drug: buspirone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: buspirone (10 mg)
Study: 6353523
Drug: secobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: secobarbital (100 mg)
Study: 3889230
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with methotrexate and leucovorin followed by regional therapy and additional methotrexate courses every three months for one year.
Study: 3889230
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with a combination of Adriamycin and cisplatin every three weeks for four cycles after the first 35 patients.
Study: 27194493
Drug: TXA IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA IV and IA group (1 g IV preoperatively and 3 g IA postoperatively)
Study: 27194493
Drug: TXA IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA IV and placebo group (1 g IV preoperatively and 100 mL saline IA)
Study: 24915800
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg.kg(‐1) loading dose followed by 0.5 μg.kg(‐1).h(‐1) infusion)
Study: 24915800
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% (bolus and infusion of equivalent volume)
Study: 14651279
Drug: Dental-bonding agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental-bonding agent (Solist) followed by resin composite (Ecusit)
Study: 16921044
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus tamoxifen
Study: 8687150
Drug: Tamoxifen or
Normalized name: tamoxifen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen or chemotherapy plus tamoxifen
Study: 6441224
Drug: Cefonicid 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid 1.0 g
Study: 6441224
Drug: Penicillin 4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin 4.8 X 10(6) units plus 1.0 g of probenecid
Study: 30616462
Drug: Gastric H.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric H. pylori treatment plus periodontal therapy